Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says

Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme